Journey Medical (DERM) Competitors

Fortress Biotech (NASDAQ:FBIO) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Does the media favor FBIO or DERM?

In the previous week, Journey Medical had 14 more articles in the media than Fortress Biotech. MarketBeat recorded 24 mentions for Journey Medical and 10 mentions for Fortress Biotech. Journey Medical's average media sentiment score of 0.07 beat Fortress Biotech's score of -0.85 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative
Journey Medical	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Is FBIO or DERM more profitable?

Journey Medical has a net margin of -15.49% compared to Fortress Biotech's net margin of -24.84%. Journey Medical's return on equity of -48.69% beat Fortress Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	-24.84%	-301.81%	-27.48%
Journey Medical	-15.49%	-48.69%	-11.26%

Which has stronger valuation and earnings, FBIO or DERM?

Journey Medical has lower revenue, but higher earnings than Fortress Biotech. Journey Medical is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$57.67M	1.12	-$46M	-$1.05	-2.06
Journey Medical	$56.13M	2.94	-$14.67M	-$0.38	-18.63

Do analysts prefer FBIO or DERM?

Fortress Biotech presently has a consensus target price of $16.50, indicating a potential upside of 662.12%. Journey Medical has a consensus target price of $10.83, indicating a potential upside of 53.01%. Given Fortress Biotech's stronger consensus rating and higher possible upside, research analysts clearly believe Fortress Biotech is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Journey Medical	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Do insiders & institutionals hold more shares of FBIO or DERM?

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 27.9% of Fortress Biotech shares are held by company insiders. Comparatively, 15.0% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Which has more risk and volatility, FBIO or DERM?

Fortress Biotech has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Journey Medical has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500.

Summary

Journey Medical beats Fortress Biotech on 9 of the 16 factors compared between the two stocks.